Patient demographics with transplant description and responses, adverse events, exposure to antibiotics for suspected or documented infection, and steroid therapy of engraftment syndrome
| Characteristic . | n = 83 . |
|---|---|
| Age, median (range), y | 64 (31-79) |
| Sex, male, n (%) | 50 (60) |
| Ethnicity, n (%) | |
| Not Hispanic or Latino | 80 (96.4) |
| Hispanic | 2 (2.4) |
| N/A | 1 (1.2) |
| Race, n (%) | |
| White | 59 (71.1) |
| Black/African American | 21 (25.3) |
| Other | 1 (1.2) |
| N/A | 2 (2.4) |
| Karnofsky performance score | |
| Median (range), % | 70 (60-100) |
| ≥70, n (%) | 74 (89.1) |
| Plasma cell disorder, n (%) | |
| MM | 79 (95.2) |
| Smoldering myeloma | 1 (1.2) |
| Plasma cell leukemia | 1 (1.2) |
| Primary light chain amyloidosis | 1 (1.2) |
| POEMS syndrome | 1 (1.2) |
| Durie-Salmon stage, n (%) | |
| I | 9 (10.8) |
| II | 16 (19.3) |
| III | 51 (61.5) |
| N/A | 7 (8.4) |
| High-risk cytogenetics, n (%) | |
| Yes | 5 (6) |
| No | 68 (82) |
| N/A | 10 (12) |
| No. of previous therapies, n (%) | |
| Range | 1-9 |
| 1 | 54 (65.1) |
| 2 | 19 (22.9) |
| 3 | 7 (8.4) |
| >3 | 3 (3.6) |
| Melphalan dose, n (%) | |
| 200 mg/m2 | 54 (65) |
| 140 mg/m2 | 29 (35) |
| Response to therapy before transplant, n (%) | |
| PD | 7 (8.4) |
| PR | 38 (45.8) |
| VGPR | 18 (21.7) |
| CR | 19 (22.9) |
| sCR | 1 (1.2) |
| Best disease response after transplant, n (%) | |
| sCR | 1 (1.2) |
| CR | 44 (53) |
| VGPR | 9 (10.8) |
| PR | 19 (23) |
| PD | 4 (4.8) |
| N/A | 6 (7.2) |
| Improved response to transplant compared with disease status before transplant, n (%) | |
| Yes | 31 (37.3) |
| No | 46 (55.4) |
| N/A | 6 (7.3) |
| Follow-up for survivors (n = 82), median (range), mo | 32 (0.7-61) |
| Progression of disease after transplant, n (%) | 33 (40.2) |
| OS at last follow-up, n (%) | 63 (76.8) |
| Adverse events, n (%) | |
| Mucositis | |
| Yes, any | 34 (41) |
| Grade 1 | 21 (25.3) |
| Grade 2 | 8 (9.6) |
| Grade ≥3 | 5 (6) |
| Nausea | |
| Yes, any | 70 (84.3) |
| Grade 1 | 39 (46.9) |
| Grade 2 | 31 (37.3) |
| Duration, median (range), d | 7.5 (1-21) |
| Vomiting | |
| Yes, any | 36 (43.4) |
| N/A | 1 (1.2) |
| Grade 1 | 34 (41) |
| Grade 2 | 2 (2.4) |
| Duration, median (range), d | 3 (1-12) |
| Diarrhea | |
| Yes, any | 75 (90.4) |
| Infectious (Clostridium difficile) | 3 (3.6) |
| Onset, median (range), d | 5 (4-12) |
| Duration, median (range), d | 8 (1-13) |
| Infectious N/A | 1 (1.2) |
| Grade 1 | 48 (57.8) |
| Grade 2 | 23 (27.7) |
| Grade 3 | 1 (1.2) |
| Grade N/A | 2 (2.9) |
| Duration, median (range), d | 7 (1-28) |
| Neutropenia | |
| Yes/N/A | 82 (98.8)/1 |
| Duration, median (range), d | 7 (3-14) |
| Neutropenic fever | 60 (72.3) |
| Major infection | |
| Yes | 19 (22.9) |
| In follow-up period/N/A | 2 (2.4)/2 (2.4) |
| Antibiotic exposure for suspected or proven infection, n (%) | 54 (65) |
| Engraftment syndrome, n (%) | |
| Yes | 23 (27.7) |
| Steroid exposure | 22 (26.5) |
| Duration of steroid exposure, median (range), d | 7.5 (2-34) |
| Nonrelapse mortality at 1 year, n (%) | 2 (2.4) |
| Characteristic . | n = 83 . |
|---|---|
| Age, median (range), y | 64 (31-79) |
| Sex, male, n (%) | 50 (60) |
| Ethnicity, n (%) | |
| Not Hispanic or Latino | 80 (96.4) |
| Hispanic | 2 (2.4) |
| N/A | 1 (1.2) |
| Race, n (%) | |
| White | 59 (71.1) |
| Black/African American | 21 (25.3) |
| Other | 1 (1.2) |
| N/A | 2 (2.4) |
| Karnofsky performance score | |
| Median (range), % | 70 (60-100) |
| ≥70, n (%) | 74 (89.1) |
| Plasma cell disorder, n (%) | |
| MM | 79 (95.2) |
| Smoldering myeloma | 1 (1.2) |
| Plasma cell leukemia | 1 (1.2) |
| Primary light chain amyloidosis | 1 (1.2) |
| POEMS syndrome | 1 (1.2) |
| Durie-Salmon stage, n (%) | |
| I | 9 (10.8) |
| II | 16 (19.3) |
| III | 51 (61.5) |
| N/A | 7 (8.4) |
| High-risk cytogenetics, n (%) | |
| Yes | 5 (6) |
| No | 68 (82) |
| N/A | 10 (12) |
| No. of previous therapies, n (%) | |
| Range | 1-9 |
| 1 | 54 (65.1) |
| 2 | 19 (22.9) |
| 3 | 7 (8.4) |
| >3 | 3 (3.6) |
| Melphalan dose, n (%) | |
| 200 mg/m2 | 54 (65) |
| 140 mg/m2 | 29 (35) |
| Response to therapy before transplant, n (%) | |
| PD | 7 (8.4) |
| PR | 38 (45.8) |
| VGPR | 18 (21.7) |
| CR | 19 (22.9) |
| sCR | 1 (1.2) |
| Best disease response after transplant, n (%) | |
| sCR | 1 (1.2) |
| CR | 44 (53) |
| VGPR | 9 (10.8) |
| PR | 19 (23) |
| PD | 4 (4.8) |
| N/A | 6 (7.2) |
| Improved response to transplant compared with disease status before transplant, n (%) | |
| Yes | 31 (37.3) |
| No | 46 (55.4) |
| N/A | 6 (7.3) |
| Follow-up for survivors (n = 82), median (range), mo | 32 (0.7-61) |
| Progression of disease after transplant, n (%) | 33 (40.2) |
| OS at last follow-up, n (%) | 63 (76.8) |
| Adverse events, n (%) | |
| Mucositis | |
| Yes, any | 34 (41) |
| Grade 1 | 21 (25.3) |
| Grade 2 | 8 (9.6) |
| Grade ≥3 | 5 (6) |
| Nausea | |
| Yes, any | 70 (84.3) |
| Grade 1 | 39 (46.9) |
| Grade 2 | 31 (37.3) |
| Duration, median (range), d | 7.5 (1-21) |
| Vomiting | |
| Yes, any | 36 (43.4) |
| N/A | 1 (1.2) |
| Grade 1 | 34 (41) |
| Grade 2 | 2 (2.4) |
| Duration, median (range), d | 3 (1-12) |
| Diarrhea | |
| Yes, any | 75 (90.4) |
| Infectious (Clostridium difficile) | 3 (3.6) |
| Onset, median (range), d | 5 (4-12) |
| Duration, median (range), d | 8 (1-13) |
| Infectious N/A | 1 (1.2) |
| Grade 1 | 48 (57.8) |
| Grade 2 | 23 (27.7) |
| Grade 3 | 1 (1.2) |
| Grade N/A | 2 (2.9) |
| Duration, median (range), d | 7 (1-28) |
| Neutropenia | |
| Yes/N/A | 82 (98.8)/1 |
| Duration, median (range), d | 7 (3-14) |
| Neutropenic fever | 60 (72.3) |
| Major infection | |
| Yes | 19 (22.9) |
| In follow-up period/N/A | 2 (2.4)/2 (2.4) |
| Antibiotic exposure for suspected or proven infection, n (%) | 54 (65) |
| Engraftment syndrome, n (%) | |
| Yes | 23 (27.7) |
| Steroid exposure | 22 (26.5) |
| Duration of steroid exposure, median (range), d | 7.5 (2-34) |
| Nonrelapse mortality at 1 year, n (%) | 2 (2.4) |
CR, complete response; N/A, not assessed or not available; PD, progression of disease; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes; PR, partial response; sCR, stringent complete response; VGPR, very good partial response.